Michelle Hoffman

Article

This is the bio for Michelle Hoffman, editor-in-chief of Pharmaceutical Technology magazine.

Michelle Hoffman
Editor-in-chief
732.346.3014, mhoffman@advanstar.com

Michelle joined Pharmaceutical Technology in 2007. She previously served as editor-in-chief of Drug Discovery & Development, G&P, and BioPerform. She has served as the senior science editor for Harvard Medical School followed by almost a decade as the associate editor (life sciences) for American Scientist magazine. In addition, she was formerly a member of the news staff at Science magazine and an editor at Cell. During her business career, she has been a member of the launch teams of two biotech startups, Quantum Genomics (functional genomics) and Karyogen (drug discovery). Michelle also analyzed new ventures at BD Technologies (part of Becton Dickinson) as a member of the business development group. She was trained in molecular biology at Brown and Harvard and holds an MBA from the University of North Carolina at Chapel Hill, where she specialized in corporate finance and entrepreneurship.

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content